Table 1.
Brief summary of clinical trials of lowering BP in hypertension
| Subjects | Agent | Effects | Reference |
|---|---|---|---|
| Children and adolescent with hypertension | AP | A reduction in BP, plasma renin activity and systemic vascular resistance | 43 |
| Prehypertensive obese adolescents | AP | A reduction in BP and body weight | 75 |
| Adolescent with primary hypertension | AP (with ACEi) | A reduction in BP (further reduction with ACEi) | 76 |
| Hypertensive adults | Fx | Fail to lower BP except in those with normal kidney function (40% subject were on RAS inhibitor) | 77 |
| Older subjects with recent ischemic attack or stroke | AP | A reduction in BP Less progression of carotid intimal thickness | 78 |
| Type 2 diabetic with normal renal function | AP | Improvement in blood pressure, kidney function, insulin resistance, and inflammation | 79 |
| Prehypertensive with mild hyperuricemia | AP | Dipping pattern of BP were observed | 80 |
| Gouty patients | Pegloticase | A reduction in BP | 81 |
| Normotensive subjects | Minor reduction in systolic BP in subject with asymptomatic hyperuricemia | 82,83,84 | |
| Normotensive subjects with anti-hypertensive agents | XO inhibitor | No effect on BP A reduction in plasma renin activity and plasma aldosterone in hyperuricemic subjects | 85,86 |
| Hypertensive and CKD patients | Febuxostat | A reduction in BP | 87 |
| CKD subjects | Removing AP | BP and renal function got worse in subjects who were not on RAS inhibitors. | 88 |
| Volunteers on low fructose diet | AP | A reduction in BP and serum UA | 89 |
| Overweight | Low fructose diet (with AP) | A reduction in BP (BP was further reduced with AP) | 80 |